Practice of antiplatelet therapy in acute myocardial infarction

Abstract

Introduction: In patients who have survived myocardial infarction, platelet aggregation inhibitor (TAG) treatment plays an important role in preventing recurrent ischemic events. Objective: to investigate the proportion of patients who received aspirin, clopidogrel, prasugrel and ticagrelor during the hospitalization and the proportion of patients who continued taking the recommended therapy during follow-up. All patients treated for myocardial infarction who had a medical ID number were included in the study. Results: 16 273 patients had ST-elevation (STEMI) and 20 305 patients had non-ST-elevation (NSTEMI) infarction. 80% of patients were hypertensive. Diabetes mellitus (35%) and impaired renal function (30%) were demonstrated in one in three patients. The TAG treatment recommendation was analysed in 36 578 patients who left the hospital. Clopidogrel 12.7%, prasugrel 4.3%, ticagrelor, 93.9%, 77.7%, 8.3% and 3.2% were found in the NSTEMI group. For medicines available under special conditions (prasugrel, ticagrelor), there were significant differences between cen­tres: the proposal varied between 1.2–4.3% for prasugrel and 0.3–10.8% for ticagrelor. Drug switching events were monitored using the National Institute of Health Insurance Fund database. Pharmacovigilance data were available for 29 405 patients. We considered the longest period in the adherence study, and the grace period was 2 months. Adherence durations were processed using a standard survival analysis toolkit (Kaplan–Meier method). At 1 year after the first switch, 76.1%, 78.3%, and 80.9% of the patients in clopidogrel, prasugrel and ticagrelor were adherents to the recommended treatment. Conclusion: The frequency of use of certain antiplatelet drugs varies significantly across different intervention centres. More than three-quarters of the patients are adherent to treatment 1 year after starting treatment.

• Authors: András Jánosi, Tamás Ferenci, Gábor Bársony, Anikó Szabóné Póth, Péter Vajer, Péter Andréka
• Journal: Orvosi hetilap (Orv Hetil) Vol. 163 Issue 19 Pg. 743-749 (May 08 2022) ISSN: 1788-6120 [Electronic] Hungary
• Vernacular Title: A thrombocytaaggregáció-gátló kezelés gyakorlata heveny szívinfarktusban
• PMID: 35526182 (Publication Type: Journal Article)

Chemical References

• Platelet Aggregation Inhibitors
• Clopidogrel
• Prasugrel Hydrochloride
• Ticagrelor

Topics

• Clopidogrel
• Humans
• Hungary
• Myocardial Infarction (therapy)
• Non-ST Elevated Myocardial Infarction
• Platelet Aggregation Inhibitors (therapeutic use)
• Prasugrel Hydrochloride
• ST Elevation Myocardial Infarction
• Ticagrelor